Organovo (NASDAQ:ONVO) and Aevi Genomic Medicine (NASDAQ:GNMX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Analyst Ratings

This is a summary of current recommendations for Organovo and Aevi Genomic Medicine, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organovo 0 0 2 0 3.00
Aevi Genomic Medicine 0 1 0 0 2.00

Organovo presently has a consensus price target of $2.13, indicating a potential upside of 312.86%. Given Organovo’s stronger consensus rating and higher possible upside, research analysts plainly believe Organovo is more favorable than Aevi Genomic Medicine.

Volatility and Risk

Organovo has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Aevi Genomic Medicine has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500.

Profitability

This table compares Organovo and Aevi Genomic Medicine’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Organovo -861.70% -70.01% -63.41%
Aevi Genomic Medicine N/A -264.47% -178.44%

Earnings & Valuation

This table compares Organovo and Aevi Genomic Medicine’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Organovo $3.09 million 21.70 -$26.64 million ($0.23) -2.24
Aevi Genomic Medicine N/A N/A -$30.77 million ($0.50) -0.35

Organovo has higher revenue and earnings than Aevi Genomic Medicine. Organovo is trading at a lower price-to-earnings ratio than Aevi Genomic Medicine, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

43.0% of Organovo shares are owned by institutional investors. Comparatively, 6.4% of Aevi Genomic Medicine shares are owned by institutional investors. 3.5% of Organovo shares are owned by company insiders. Comparatively, 44.3% of Aevi Genomic Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Organovo beats Aevi Genomic Medicine on 10 of the 13 factors compared between the two stocks.

About Organovo

Organovo Holdings, Inc., a biotechnology company, provides therapeutic and drug profiling capabilities based on its 3D bioprint tissues that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat a range of rare, life-threatening diseases. In addition, the company offers preclinical in vitro disease modeling platforms, including a range of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis conditions. Further, it involved in various programs to develop its NovoTissues transplantable tissues to address various serious unmet medical needs in adult and pediatric populations primarily focusing on liver disease. The company was founded in 2007 and is headquartered in San Diego, California.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, which is in preclinical stage for the treatment of pediatric rare diseases. It has a strategic collaboration with Kyowa Hakko Kirin Co., Ltd. for an early stage monoclonal antibody program in an ultra-orphan pediatric indication. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.